DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,596,110 | +11.5% | 38,679 | +7.8% | 0.86% | +17.4% |
| Q2 2023 | $8,609,280 | -1.1% | 35,872 | +3.8% | 0.73% | -6.1% |
| Q1 2023 | $8,708,338 | -2.8% | 34,552 | +2.3% | 0.78% | -5.6% |
| Q4 2022 | $8,963,263 | +12.1% | 33,772 | +9.0% | 0.82% | +2.5% |
| Q3 2022 | $7,999,000 | +3.7% | 30,972 | +1.8% | 0.80% | +5.1% |
| Q2 2022 | $7,711,000 | -11.0% | 30,415 | +3.0% | 0.76% | +7.5% |
| Q1 2022 | $8,662,000 | -5.0% | 29,531 | +6.6% | 0.71% | +0.7% |
| Q4 2021 | $9,117,000 | +1.8% | 27,711 | -5.8% | 0.70% | +23.5% |
| Q3 2021 | $8,954,000 | +56.7% | 29,411 | +38.2% | 0.57% | +53.6% |
| Q2 2021 | $5,713,000 | +16.3% | 21,288 | -2.4% | 0.37% | +13.5% |
| Q1 2021 | $4,912,000 | -0.4% | 21,822 | -1.7% | 0.33% | -3.8% |
| Q4 2020 | $4,933,000 | -1.1% | 22,208 | -4.1% | 0.34% | -10.5% |
| Q3 2020 | $4,989,000 | +15.6% | 23,168 | -5.1% | 0.38% | +4.4% |
| Q2 2020 | $4,317,000 | +19.6% | 24,415 | -6.4% | 0.36% | -22.1% |
| Q1 2020 | $3,610,000 | -10.5% | 26,080 | -0.8% | 0.47% | +13.1% |
| Q4 2019 | $4,035,000 | -2.8% | 26,291 | -8.5% | 0.41% | -6.3% |
| Q3 2019 | $4,152,000 | +51.6% | 28,746 | +50.0% | 0.44% | +1.1% |
| Q2 2019 | $2,739,000 | +4.7% | 19,164 | -3.3% | 0.44% | +3.3% |
| Q1 2019 | $2,616,000 | +32.4% | 19,809 | +3.4% | 0.42% | +11.3% |
| Q4 2018 | $1,976,000 | -8.6% | 19,164 | -3.7% | 0.38% | +6.8% |
| Q3 2018 | $2,163,000 | +3.6% | 19,907 | -5.9% | 0.36% | -2.2% |
| Q2 2018 | $2,087,000 | +4.1% | 21,144 | +3.3% | 0.36% | +7.7% |
| Q1 2018 | $2,005,000 | +1.3% | 20,477 | -4.0% | 0.34% | 0.0% |
| Q4 2017 | $1,979,000 | +0.1% | 21,327 | -7.5% | 0.34% | -1.5% |
| Q3 2017 | $1,978,000 | -18.6% | 23,065 | -20.0% | 0.34% | -49.1% |
| Q2 2017 | $2,431,000 | -28.6% | 28,815 | -27.7% | 0.67% | -29.2% |
| Q1 2017 | $3,407,000 | +10.2% | 39,835 | +0.3% | 0.95% | +3.6% |
| Q4 2016 | $3,092,000 | +7.5% | 39,725 | +8.2% | 0.92% | -0.7% |
| Q3 2016 | $2,877,000 | +6.4% | 36,702 | +37.1% | 0.92% | +3.5% |
| Q2 2016 | $2,704,000 | +19.0% | 26,774 | +11.7% | 0.89% | +10.7% |
| Q1 2016 | $2,273,000 | -18.1% | 23,962 | -19.8% | 0.80% | -17.7% |
| Q4 2015 | $2,774,000 | -0.5% | 29,866 | -8.7% | 0.98% | -1.8% |
| Q3 2015 | $2,788,000 | +45.4% | 32,718 | +46.0% | 1.00% | +66.3% |
| Q2 2015 | $1,917,000 | -1.1% | 22,404 | -1.9% | 0.60% | +0.2% |
| Q1 2015 | $1,939,000 | +15.1% | 22,832 | +16.1% | 0.60% | +13.5% |
| Q4 2014 | $1,685,000 | +8.9% | 19,659 | -3.4% | 0.53% | +6.7% |
| Q3 2014 | $1,547,000 | -1.5% | 20,359 | +2.1% | 0.49% | +1.0% |
| Q2 2014 | $1,570,000 | +3.6% | 19,944 | -1.3% | 0.49% | 0.0% |
| Q1 2014 | $1,516,000 | -5.1% | 20,209 | -2.3% | 0.49% | -6.7% |
| Q4 2013 | $1,597,000 | +11.5% | 20,695 | +0.2% | 0.52% | +8.0% |
| Q3 2013 | $1,432,000 | +9.1% | 20,664 | -0.4% | 0.48% | +4.1% |
| Q2 2013 | $1,313,000 | – | 20,746 | – | 0.47% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |